This preprint is under consideration at Tropical Diseases, Travel Medicine and Vaccines. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Short report
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Introduction. Currently, more than 1.8 billion doses of SARS-CoV-2 vaccines have been applied worldwide. However, some developing countries are still a long way from achieving herd immunity through vaccination. In some territories, such as the Colombian Amazon, mass immunization strategies have been implemented with the CoronaVac® vaccine. Due to its proximity to Brazil, where one of the variants of interest of SARS-CoV-2 circulates.
Objective. To determine the efficacy of the CoronaVac® vaccine in a population of the Colombian Amazon.
Methods. Between February 24, 2021, and May 19, 2021, a descriptive observational study was carried out in which a population of individuals over 18 years of age immunized with two doses of the CoronaVac® vaccine was evaluated. The study site was in the municipality of Mitú, Vaupés, in southeastern Colombia, a region located in the Amazon bordering Brazil. Results. 87% of the urban population of the Mitú municipality were vaccinated with CoronaVac®. To date, 2.1% of vaccinated individuals have become ill, and only 0.1% of these require hospitalization. No deaths attributable to COVID-19 have been reported among vaccinated individuals, and the vaccine has shown 97% efficacy against mild disease and 100% against severe infection.
Conclusions. The herd immunity achieved through mass vaccination in this population has made it possible to reduce the rate of complicated cases and mortality from COVID-19 in this region of the Colombian Amazon.
Keywords
COVID-19 vaccines, Prevention, post-exposure, Prophylaxis, Public health, Mass vaccination
Figure 1
Figure 2
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 18 Jun, 2021
No community comments so far
Editorial decision: Major revision
On 10 Aug, 2021
Review #4 received
Received 04 Aug, 2021
Reviewer #5 agreed
On 21 Jul, 2021
Review #5 received
Received 21 Jul, 2021
Review #1 received
Received 18 Jul, 2021
Review #3 received
Received 18 Jul, 2021
Review #2 received
Received 16 Jul, 2021
Reviewer #4 agreed
On 05 Jul, 2021
Reviewer #2 agreed
On 27 Jun, 2021
Reviewer #3 agreed
On 27 Jun, 2021
Reviews received
Received 27 Jun, 2021
Reviewer #1 agreed
On 27 Jun, 2021
Reviewers invited
Invitations sent on 24 Jun, 2021
Editor assigned
On 08 Jun, 2021
Submission checks complete
On 08 Jun, 2021
Editor invited
On 08 Jun, 2021
First submitted
On 04 Jun, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This preprint is under consideration at Tropical Diseases, Travel Medicine and Vaccines. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Short report
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 18 Jun, 2021
No community comments so far
Editorial decision: Major revision
On 10 Aug, 2021
Review #4 received
Received 04 Aug, 2021
Reviewer #5 agreed
On 21 Jul, 2021
Review #5 received
Received 21 Jul, 2021
Review #1 received
Received 18 Jul, 2021
Review #3 received
Received 18 Jul, 2021
Review #2 received
Received 16 Jul, 2021
Reviewer #4 agreed
On 05 Jul, 2021
Reviewer #2 agreed
On 27 Jun, 2021
Reviewer #3 agreed
On 27 Jun, 2021
Reviews received
Received 27 Jun, 2021
Reviewer #1 agreed
On 27 Jun, 2021
Reviewers invited
Invitations sent on 24 Jun, 2021
Editor assigned
On 08 Jun, 2021
Submission checks complete
On 08 Jun, 2021
Editor invited
On 08 Jun, 2021
First submitted
On 04 Jun, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Introduction. Currently, more than 1.8 billion doses of SARS-CoV-2 vaccines have been applied worldwide. However, some developing countries are still a long way from achieving herd immunity through vaccination. In some territories, such as the Colombian Amazon, mass immunization strategies have been implemented with the CoronaVac® vaccine. Due to its proximity to Brazil, where one of the variants of interest of SARS-CoV-2 circulates.
Objective. To determine the efficacy of the CoronaVac® vaccine in a population of the Colombian Amazon.
Methods. Between February 24, 2021, and May 19, 2021, a descriptive observational study was carried out in which a population of individuals over 18 years of age immunized with two doses of the CoronaVac® vaccine was evaluated. The study site was in the municipality of Mitú, Vaupés, in southeastern Colombia, a region located in the Amazon bordering Brazil. Results. 87% of the urban population of the Mitú municipality were vaccinated with CoronaVac®. To date, 2.1% of vaccinated individuals have become ill, and only 0.1% of these require hospitalization. No deaths attributable to COVID-19 have been reported among vaccinated individuals, and the vaccine has shown 97% efficacy against mild disease and 100% against severe infection.
Conclusions. The herd immunity achieved through mass vaccination in this population has made it possible to reduce the rate of complicated cases and mortality from COVID-19 in this region of the Colombian Amazon.
Figure 1
Figure 2
Loading...